Curis Stock Forecast, Price & News

Curis (NASDAQ:CRIS) Frequently Asked Questions

Is Curis a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Curis stock.
View analyst ratings for Curis or view top-rated stocks.

How has Curis' stock price been impacted by Coronavirus (COVID-19)?

Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRIS stock has increased by 311.9% and is now trading at $4.49.
View which stocks have been most impacted by COVID-19.

When is Curis' next earnings date?

Curis is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Curis.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. Curis had a negative net margin of 373.25% and a negative trailing twelve-month return on equity of 33.62%. During the same period in the previous year, the company posted ($0.11) EPS.
View Curis' earnings history.

When did Curis' stock split? How did Curis' stock split work?

Curis's stock reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRIS?

5 equities research analysts have issued twelve-month price objectives for Curis' shares. Their forecasts range from $15.00 to $24.00. On average, they anticipate Curis' share price to reach $19.80 in the next year. This suggests a possible upside of 341.0% from the stock's current price.
View analysts' price targets for Curis or view top-rated stocks among Wall Street analysts.

Who are Curis' key executives?

Curis' management team includes the following people:

• James E. Dentzer, President, Chief Executive Officer & Director
• William E. Steinkrauss, Chief Financial Officer & Treasurer
• Mark W. Noel, VP-Technology Management & Intellectual Property
• Robert E. Martell, Head-Research & Development
• Reinhard von Roemeling, Senior Vice President-Clinical Development

Who are some of Curis' key competitors?

Some companies that are related to Curis include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of CRIS's competitors.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (8.27%), Lord Abbett & CO. LLC (3.81%), Polar Capital Holdings Plc (3.51%), Candriam Luxembourg S.C.A. (3.30%), Emerald Advisers LLC (2.22%) and Emerald Mutual Fund Advisers Trust (2.16%).
View institutional ownership trends for Curis.

Which institutional investors are selling Curis stock?

CRIS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Two Sigma Investments LP, Citigroup Inc., Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, Jane Street Group LLC, Lord Abbett & CO. LLC, and Affinity Asset Advisors LLC.
View insider buying and selling activity for Curis or view top insider-selling stocks.

Which institutional investors are buying Curis stock?

CRIS stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Polar Capital Holdings Plc, Candriam Luxembourg S.C.A., UBS Group AG, Los Angeles Capital Management LLC, Morgan Stanley, HighVista Strategies LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Curis or or view top insider-buying stocks.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $4.49.

How much money does Curis make?

Curis has a market capitalization of $411.32 million and generates $10.84 million in revenue each year. The biotechnology company earns $-29.91 million in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does Curis have?

Curis employs 28 workers across the globe.

When was Curis founded?

Curis was founded in 2000.

What is Curis' official website?

The official website for Curis is www.curis.com.

Where are Curis' headquarters?

Curis is headquartered at 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (617) 503-6500, via email at [email protected], or via fax at 617-503-6501.